The drug is already approved for KMT2A-rearranged AML, and Syndax is hoping for approval in NPM1-mutated disease by the end of the year.

The company plans to use some of the funds to support development of a kinase inhibitor in Phase I testing for BCR-ABL fusion-positive chronic myeloid leukemia.

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

The biotech, known as the developer of the first CRISPR drug, will consolidate sites in the state as it stops developing a diabetes cell therapy.

The agency approved a perioperative Keytruda regimen based on a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.

The $1.35 billion deal is expected to close in Q3 2025, giving RayzeBio rights to the radioligand, which is already undergoing Phase I testing as a diagnostic.

The firm will use the funds to further develop its lead genetic medicine in Stargardt disease and advance its gene therapy pipeline in other indications.